NW-301V / Neowise Biotech - LARVOL DELTA

First-in-human phase I study of TCR-T therapy targeting KRAS G12V in metastatic solid tumors (ESMO 2025) - "Pts undergo apheresis for NW-301V manufacture, and lymphodepletion (LD) with fludarabine (30mg/m 2 /day) and cyclophosphamide (500mg/m 2 /day) for 3 days, prior to NW-301V infusion. Ongoing dose escalation aims to further assess anti-tumor efficacy at higher doses and establish the RP2D. Legal entity responsible for the study The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China."

First-in-human • Metastases • P1 data • Colorectal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CD8 • KRAS

NW-301 TCR-T in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=44 | Not yet recruiting | Sponsor: Peking University

New P1 trial • Solid Tumor

NW-301 TCR-T in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Tao Zhang

Metastases • New P1 trial • Oncology • Solid Tumor

NW-301 TCR-T in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Ting Deng

Metastases • New P1 trial • Oncology • Solid Tumor

NW-301 TCR-T in Patients With Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: TingBo Liang

Metastases • New P1 trial • Oncology • Solid Tumor